Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Accumulated Expenses (2017 - 2025)

Bioceres Crop Solutions' Accumulated Expenses history spans 9 years, with the latest figure at $6.2 million for Q2 2025.

  • On a quarterly basis, Accumulated Expenses fell 15.9% to $6.2 million in Q2 2025 year-over-year; TTM through Jun 2025 was $6.2 million, a 15.9% decrease, with the full-year FY2025 number at $6.2 million, down 15.9% from a year prior.
  • Accumulated Expenses hit $6.2 million in Q2 2025 for Bioceres Crop Solutions, down from $7.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for BIOX hit a ceiling of $14.9 million in Q4 2021 and a floor of $4.7 million in Q2 2021.
  • Historically, Accumulated Expenses has averaged $8.4 million across 5 years, with a median of $7.5 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: soared 62.8% in 2022 and later fell 23.59% in 2024.
  • Tracing BIOX's Accumulated Expenses over 5 years: stood at $14.9 million in 2021, then crashed by 48.7% to $7.6 million in 2022, then increased by 26.09% to $9.6 million in 2023, then fell by 23.59% to $7.3 million in 2024, then decreased by 15.9% to $6.2 million in 2025.
  • Business Quant data shows Accumulated Expenses for BIOX at $6.2 million in Q2 2025, $7.3 million in Q2 2024, and $9.6 million in Q2 2023.